CF PharmTech, Inc. Raises USD $65 Million to Accelerate the Development of Company#s Inhalation Products and Manufacturing Capacity to Global Market

Food and Healthcare Press Releases Monday August 28, 2017 10:44
SUZHOU, China--28 Aug--PRNewswire/InfoQuest

CF PharmTech, Inc. ("CF PharmTech"), a leading specialty pharmaceutical company that develops and manufactures inhalation products, announced today that it has raised $65M in a Series D financing. Future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited ("SDIC Fund Management"), led the financing along with other prestigious healthcare investment groups in China.

CF PharmTech, founded by seasoned industry experts and entrepreneurs with a successful track record in the US pharmaceutical industry, is focused on the development, manufacturing and commercialization of high-quality inhalation products for the global market. Since its inception, CF PharmTech has established state-of-art research and manufacturing facilities to advance its product development. This new round of investment will not only expedite the submission of its product pipeline to meet regulatory approvals in China and abroad, but also expand its CDMO service to international clients.

Mr. Hai Lu, Managing Director of SDIC Fund Management, commented: "Drug delivery via pulmonary route bears significant technical challenges and it takes extraordinary effort to bring inhalation products to the market. CF PharmTech's high caliber team has proved their ability to attract top industry talents to develop inhalation products for the global market. We are confident that they will achieve their business mission in the near future."

CF PharmTech, headquartered in Suzhou, China, develops metered dose inhaler, inhalation powder, nasal spray and blow-fill-seal products. It has established high-quality research and manufacturing environments to be compliant with US, EU and Chinese regulations. CF PharmTech aims to provide quality and cost-effective inhalation products for domestic market, and seeks strategic partnerships to co-develop and commercialize its products globally.

About SDIC Fund Management Corporation Limited

Established in July 2009, SDIC Fund Management Corporation Limited is an independent, professional private equity firm. It currently manages and advises more than RMB 50 billion of capital for a wide range of institutional investors including financial institutions, pension funds, and state-owned and private capital. SDIC Fund Management Corporation Limited is one of the largest, professional private equity fund managers in China. The core strategy of SDIC Fund Management is to invest in market leading companies with attractive growth prospects and outstanding management teams.


Latest Press Release

Covaris Introduces the 96 oneTUBE-10 AFA Plate for Improved NGS Workflows

Today, Covaris Inc. announced the release of the 96 oneTUBE-10 AFA Plate, which enables scalable and simplified workflows by leveraging Covaris' gold standard focused-acoustic technology to meet rapidly increasing Next-Generation Sequencing (NGS) demands...

2018 Empire State Building Run-Up Lottery Registration Opens on November 14, 2017

Runners must enter by December 10 for a chance to participate in the 41st Annual Run-Up on Wednesday, February 7, 2018, at 8:00 p.m. Empire State Realty Trust, Inc. (NYSE: ESRT) today announced that lottery registration for the 2018 Empire State...

Alpinion Medical Systems Launches E-CUBE 8, the New Ultrasound Diagnostic System

One of South Korea's global medical device manufacturers, Alpinion Medical Systems introduced its new E-CUBE 8, the latest and last addition to the E-CUBE lineup. The E-CUBE 8 is a smart, reliable product that ensures high performance with outstanding...

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Blueprint for Change address Diabetes challenge , aligned with national NCD targets

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk...

Stryker announces publication of the DAWN(TM) Trial results in the New England Journal of Medicine

The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from...

Related Topics